A retrospective analysis of the effect of tacrolimus conversion in different periods post-renal transplantation

Abstract

Objective To summarize the clinical characteristics of recipients of renal transplantation who used tacrolimus extended-release capsules, to optimize the postoperative immunosuppressive regimen, and provide reference for the therapeutic administration of immunosuppressive agents after renal transplantation. Methods 156 patients who had renal transplant in our center were divided into three groups according to the time of the change of the extended-release tacrolimus capsules, and the blood glucose and blood lipids of each group were analyzed. Results The longer the postoperative duration was, the higher proportion of new-onset diabetes cases (P=0.025). There was no significant difference among the three groups of immune induction regimens. The immunosuppressive regimen was changed from MMF (68.8% in G3 group) to MPA (72% in G1 group). With the prolongation of postoperative time, the dosage of tacrolimus decreased gradually. The mean tacrolimus concentration in the 3 groups was significantly different (P<0.001) as time went by. There was no significant change in the average daily dosage before and after the change. The trough value before and after the change in the first two groups was significantly different (P<0.001). Conclusion The extended-release tacrolimus capsules could be used in different stages after renal transplantation. After the conversion of the extended-release tacrolimus capsules, the dosage of adjuvant is reduced, and blood concentration and creatinine level are more stablem which is a more optimized immunosuppressive regimen. Key words: Kidney transplantation; Tacrolimus; Immunosuppressant; Retrospective study